Navigation Links
In asthma, it's not just what you smell, but what you think you smell
Date:7/22/2014

PHILADELPHIA (July 22, 2014) New research from the Monell Center reveals that simply believing that an odor is potentially harmful can increase airway inflammation in asthmatics for at least 24 hours following exposure. The findings highlight the role that expectations can play in health-related outcomes.

"Asthmatics often are anxious about scents and fragrances. When we expect that an odor is harmful, our bodies react as if that odor is indeed harmful," said study lead author Cristina Jan, PhD, a Monell physiologist. "Both patients and care providers need to understand how expectations about odors can influence symptoms of the disease."

Asthma is a chronic inflammatory disorder of the lungs. According to the National Institutes of Health, over 25 million Americans have the disease, which can interfere with quality of life. The airways of asthmatics are sensitive to 'triggers' that further inflame and constrict the airways, making it difficult to breathe. There are many different types of triggers, including pollen, dust, irritating chemicals, and allergens. Strong emotions and stress also can act to trigger asthma symptoms.

Because asthma has no cure, it is important for individuals with the disease to understand how to manage their symptoms to help prevent severe asthma attacks.

Many health organizations list scents and fragrances as asthma triggers, leading patients to become anxious when exposed to environmental odors. The current research was conducted to determine whether odor-triggered asthma symptoms can be elicited or worsened by associated negative expectations.

In the study, published online ahead of print in the Journal of Psychosomatic Research, 17 individuals characterized as moderate asthmatics were exposed to the odor phenylethyl alcohol (PEA) for 15 minutes. Often described as rose-smelling, PEA is regarded as a 'pure' odorant with no associated physiological irritant qualities.

Eight subjects were told that the odor had potential therapeutic properties, while nine were told that it potentially could cause mild respiratory problems.

During odor presentation, the subjects rated the odor's sensory properties, including intensity, irritancy, and annoyance. Measures of lung function and airway inflammation were collected before and immediately after exposure and again at two hours and 24 hours post-exposure.

Subjects' beliefs about the odor, specifically whether it was potentially harmful (asthma-triggering) or therapeutic, influenced both their psychological and physiological responses to odor exposure.

Individuals who were told that the odor was potentially harmful rated it as more irritating and annoying as compared to those who thought it might be therapeutic.

In addition, airway inflammation increased immediately following odor exposure in subjects who believed the odor might be harmful and remained elevated 24 hours later.

"Introducing a negative bias led to a rapid change in airway inflammation," said senior author Pamela Dalton, PhD, a cognitive psychologist at Monell. "What really surprised us was that this response lasted for over 24 hours. The increased inflammation during this period likely makes asthmatics more sensitive to other triggers."

There was no increase of inflammation when the odor was characterized as therapeutic, even in individuals who described themselves as sensitive to perfumes and other odors.

The findings suggest that some fragrance effects on asthma symptoms may be related to the expectation of harm as opposed to chemical properties of the odor.

"It's not just what you smell, but also what you think you smell," said Jan.

Looking forward, the researchers want to identify the biological mechanisms that connect expectations to airway inflammation. They also intend to explore whether a reverse phenomenon also exists. Dalton asks, "Can we improve health outcomes by reducing concern or fear in a disease where emotional arousal is counter-productive?"


'/>"/>

Contact: Leslie Stein
stein@monell.org
267-519-4707
Monell Chemical Senses Center
Source:Eurekalert

Related biology news :

1. Rethinking the reef
2. Stanford researchers rethink natural habitat for wildlife
3. How coughs and sneezes float farther than you think
4. Thinking it through: Scientists seek to unlock mysteries of the brain
5. Climate engineering -- what do the public think?
6. Hoyos Labs, a Digital Infrastructure Security Company, Launches; Rethinks How We Authenticate and Secure Identity
7. Fund launched to seed new thinking in sustaining the future of health
8. Researchers call for rethinking efforts to prevent interplanetary contamination
9. Major rethink needed if chemical industry is to meet greenhouse gas targets
10. A way of thinking may enable battle but prevent war crimes
11. Study prompts rethink of how ovaries develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which ... today to pursue the highest level of accuracy and quality with the addition ... and the AR5 Refractometer. Accurate, reliable and tough enough for the most ...
(Date:2/10/2016)... BioAmber Inc. (NYSE: BIOA ), a leader in ... Co. Ltd., its partner in the Sarnia ... additional CDN$25 million in the joint venture for 10% ... 40%.  Mitsui will also play a stronger role in ... Sarnia , providing dedicated resources alongside BioAmber,s commercial ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology: